CLEW Medical vs Etiometry (2026)
Both sell FDA cleared analytics for critical care, and both have marketed those clearances past their stated indications. CLEW Medical predicts clinical deterioration for bedside and tele ICU teams, with operating characteristics stated in its 510(k) summaries; its clearance covers adult critical care, and a 2024 company release put the cleared label on medical and surgical floors. Etiometry, from Dedham, Massachusetts, combines vendor neutral ICU data aggregation with four physiologic risk indices, each estimating the probability that a patient is currently in a defined physiologic state. Its FAQ claims adult clearance for all four; the current clearance covers three, for children up to 12. One index has been revalidated at a single outside site. Choose CLEW for adult ICU deterioration prediction; choose Etiometry for physiologic state estimates in pediatric critical care, within its clearance.
- Your use is adult critical care or tele ICU.
- You want deterioration predicted as an outcome, not a physiologic state.
- Operating characteristics should be stated in a 510(k) summary.
- You need ICU data aggregated across device vendors.
- Your patients are children in critical care, within the cleared indication.
- An outside site's revalidation matters to your committee.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. CLEW Medical and Etiometry are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | CLEW Medical | Etiometry |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Inpatient Deterioration & Risk Monitoring |
| Headquarters | Netanya, Israel | Dedham, Massachusetts, United States |
| Website | clewmed.com | etiometry.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
CLEW Medical, based in Netanya, Israel, with US operations in Boston, sells FDA cleared machine learning models that predict clinical deterioration in hospital critical care, delivered through a clinical surveillance platform for bedside and tele-ICU teams. Its operating characteristics are public because the models are regulated as medical devices and the 510(k) summaries state them.
Source: AI Health Index, September 2026
Etiometry, based in Dedham, Massachusetts, sells a clinical intelligence platform for critical care that combines vendor neutral ICU data aggregation with four FDA cleared physiologic risk indices. The indices do not predict a coded outcome; each estimates the probability that a patient is currently in a defined physiologic state, specified against a laboratory threshold.
Source: AI Health Index, September 2026
Questions buyers ask
How do CLEW Medical and Etiometry work with the EHR?
For CLEW Medical, the 510(k) describes the server importing EHR and bedside monitor data over an HL7 connection, the sensible choice for device streams that FHIR serves poorly, and a heavier build than an app.
The FAQ describes Epic and Oracle Health (Cerner) sending admissions and laboratory results over standard HL7 interfaces, with medications, procedures and diagnoses captured through Etiometry's FHIR application and SMART on FHIR single sign-on, and Meditech over HL7. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for CLEW Medical and Etiometry?
CLEWHI reached 63 and 69 percent sensitivity, 93 and 87 percent specificity, and 12 and 10 percent positive predictive value; CLEWLR reached 47 and 35.5 percent sensitivity at about 90 percent specificity, all against targets set before testing.
For Etiometry, the home page leads with "Reduce Length of Stay by up to 36%" and readmissions "by up to 41%". The 36 percent traces to a 2017 conference abstract (Salvin, Circulation supplement). From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How much do CLEW Medical and Etiometry leave to the clinician?
CLEWHI flags patients likely to need vasopressor or inotrope support within eight hours; CLEWLR labels patients as low risk of deterioration, a label a unit may lean on when deciding who can step down.
In Etiometry's case, the company states repeatedly that the platform is not an active patient monitoring or alarm system, provides adjunctive information and informational flags, supplements rather than replaces monitoring, must not be the sole source of patient status information, and leaves clinicians responsible for all assessment and treatment decisions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
CLEW's site could not be read at review, so parts of its record rest on earlier reads; Etiometry's record was reviewed on this site in September 2026. Neither publishes a price. Etiometry calls itself the only company in the world with four cleared risk algorithms, a claim this page does not rely on.
Ask both to show the indication in their 510(k) letter, and which of your patients it covers.